Why Moderna (MRNA) Shares Are Trading Higher Today
[ad_1] The U.S. government has secured 66 million doses of Moderna Inc’s MRNA COVID-19 vaccine booster candidate, mRNA-1273.222, a bivalent booster candidate containing Spikevax plus the omicron BA.4/5 strain mRNA. The contract…
Why Smith & Nephew (SNN) Shares Are Falling Today
[ad_1] Smith & Nephew Plc SNN reported Q2 revenue of $1.29 billion, up 1.2% on an underlying basis but down 3.1% on a reported basis, including a 430 basis point foreign…
Daily Biotech Pulse: Teva’s Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio’s Leukemia Therapy
[ad_1] Here’s a roundup of top developments in the biotech space over the last 24 hours: The Justice Department has opened a criminal investigation into Cassava Sciences Inc SAVA on whether it…
Medical Cost Trends Benefit Humana Q2 Earnings, Raises FY22 Profit Outlook
[ad_1] Humana Inc HUM has posted Q2 adjusted sales of $23.72 billion, beating the consensus of $23.47 billion. The benefits expense ratio remained unchanged at 85.8%, and the operating cost…
Silk Road Medical’s Q2 Margins Hit By Manufacturing Expansion Costs
[ad_1] Silk Road Medical Inc SILK posted Q2 revenue of $33.2 million, an increase of 25% Y/Y, driven primarily by increased TCAR adoption, beating the consensus of $31.16 million. “We…
With FDA Submission, Cidara Therapeutics Inks US Pact For Bloodstream Infection Candidate
[ad_1] Cidara Therapeutics Inc CDTX has submitted a marketing application to the FDA seeking approval for rezafungin for candidemia and invasive candidiasis. The company has also entered into a license agreement…
Woman-Health Focused Stock Agile Therapeutics Is ‘Better Positioned,’ Analyst Says While Upgrading Stock
[ad_1] Maxim Group upgraded Agile Therapeutics Inc AGRX to Buy from Hold with a price target of $1, saying it should be better positioned to begin to rebound. Agile recently closed…
Why vTv Therapeutics (VTVT) Shares Are Jumping Today
[ad_1] CinPax LLC has acquired around 4.1 million shares of vTv Therapeutics Inc VTVT at approximately $2.41 per share, with $6 million paid in cash at closing and the remaining $4 million payable on…
This Analyst Says GSK Spin-Off Haleon Offers “Best Of Both Consumer Worlds”
[ad_1] Citi group has initiated coverage on GSK plc’s GSK consumer healthcare spin-off Haleon Plc HLN with a Buy rating and a price target of 360p. “We see the company as the best…
Semiconductor Shortages – See How ResMed Is Tackling
[ad_1] ResMed Inc RMD has redesigned the AirSense 10 to eliminate a short-supply semiconductor chipset used for cellular communications chips. Instead of offering wireless communications capability, the new AirSense…
Daily Biotech Pulse: VistaGen’s Anxiety Study Fails, Silverback To Merge With Firm Developing EpiPen Alternative, Setback For Liminal’s Lead Asset
[ad_1] Here’s a roundup of top developments in the biotech space over the last 24 hours: VistaGen Therapeutics Inc VTGN has announced topline results from its PALISADE-1 Phase 3 trial of PH94B for…
Tenet Healthcare Posts Lower Sales, Profits On Unfavorable Impact Of Cyber Attack
[ad_1] by Vandana Singh, Benzinga Editor July 22, 2022 6:06 AM | 1 min read Same-hospital net patient service revenue per adjusted admission decreased 0.2% due to the cybersecurity incident.…
HilleVax’s Norovirus Vaccine Shows Long-Term Immunogenicity
[ad_1] HilleVax Inc HLVX announced results from the NOR-213 Phase 2 trial of HIL-214, a virus-like particle (VLP) based vaccine for preventing moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Norovirus…
Quest Diagnostics (DGX) Q2 Earnings
[ad_1] Quest Diagnostics Inc DGX posted a better-than-expected Q2 FY22 adjusted EPS of $2.36, though down 25.8% Y/Y, beating the consensus of $2.20. Sales came in at $2.45 billion, a…
Earnings Beat, Increased FY22 Outlook, Rising Biosimilar Competition: Biogen’s Q2 Highlights
[ad_1] Biogen Inc BIIB has posted Q2 sales of $2.59 billion, beating the consensus of $2.48 billion, down 7% Y/Y and 5% at constant currency (CC). Multiple sclerosis revenue, including…
Medigus’ Polyrizon Inks Agreement To Develop Therapies For Traumatic Spinal Cord Injuries
[ad_1] Polyrizon Ltd, in which Medigus Ltd MDGS owns a 37.03% stake, signed a binding Collaboration Agreement with NurExone Biologic Inc for therapies for traumatic spinal cord injuries. Polyrizon is an Israeli biotech company specializing…